---
title: "GI Stromal Tumors"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    #css: ["theme/theme.css"]
    theme: default
      
    echo: false
editor: visual
bibliography: zotero.bib
---

## GI Stromal Tumors


## ACOSOG ZZ9001

GIST Tumors \>3cm randomized: - 1 year of imatinib 40mg - Observation

Recurrence-free survival 98% vs 83% No significant difference at 6 years

*Imatinib may simply delay recurrences*

::: aside
Ref
:::

## SSG SVII

High-risk GIST randomized: - 1 year of imatinib 400mg - 3 year of imatinib 400mg

5-year Recurrence-free survival 48% vs 66% 5-year Overall Survival 82% vs 92%

::: aside
Ref
:::

## Mutational Testing

Genetic mutations can predict respoinse to imatinib [^1]

[^1]: Meheran JCO 2017



-   ChemoRT $\rightarrow$ Surgery (\[CROSS Trial\])
-   Chemo $\rightarrow$ Surgery $\rightarrow$ Chemo ([EsoPEC Trial])

## Positive Margins

-   368 esophageal cancer patients randomized:
    -   Surgery alone
    -   Chemo+RT $\rightarrow$ Surgery
-   75% adenocarcinoma
-   T3: 80%. T2: 17%
-   median age=60
-   longer survival with Chemo+RT $\rightarrow$ Surgery

::: aside
Gronchi JAMA Surg 2020
:::

## Imatinib 1yr vs 3 yr

-   368 esophageal cancer patients randomized:
    -   Surgery alone
    -   Chemo+RT $\rightarrow$ Surgery
-   75% adenocarcinoma
-   T3: 80%. T2: 17%
-   median age=60
-   longer survival with Chemo+RT $\rightarrow$ Surgery

::: aside
Joensuu JAMA Oncology 2020
:::

## Wild-Type GIST

-   SDH-Deficient
    -   SDHx mutation
    -   SDH wild-type
    -   Associated with Carney-Stratakis syndrome
-   No SDH Deficiency
    -   NF1-GIST
    -   Sporadic Wild-Type GIST

::: aside
Weldon JCS 2017
:::

## NF1-associated GIST

-   Multicentric (33%)
-   Median age 46
-   Small bowel \>\> Duodenum \>\> Stomach

::: aside
Weldon JCS 2017
:::

## Recurrence Risk

::: aside
Joensuu Lancet March 2012
:::

## CROSS - Risk Classification



::: aside
Miettinen Lasota Seminars in Diagnostic Pathology 2006:23:70-83
:::


# Orientation Manual

{{< qrcode https://gisurgonc.github.io/orientation width=500 height=500 >}}

# References
